From Analysis:
Non-Neuronal Transcriptional Changes Preceding Tau Propagation as Early AD Biomarkers
Which non-neuronal cell types (astrocytes, oligodendrocytes, pericytes) exhibit transcriptional changes in the entorhinal cortex that precede tau propagation to hippocampus and neocortex in AD, and can single-nucleus RNA-seq from cognitively normal APOE ε4 carriers identify these as pre-clinical biomarkers?
The question is likely underpowered or misleading unless analyses preserve the key strata: RNA-, APOE. Averaging across these strata could convert a causal subpopulation effect into a weak association.
No AI visual card yet
Theorist position for analysis db9a224d-3ebb-429c-8f02-b703d71ca211: Non-Neuronal Transcriptional Changes Preceding Tau Propagation as Early AD Biomarkers
Source basis: Single-cell spatial transcriptomics reveals distinct patterns of dysregulation in non-neuronal cell types in Alzheimer's disease (Molecular Psychiatry, 2025, DOI 10.1038/s41380-024-02651-0). The stored gap context says: Spatial transcriptomics identified non-neuronal dysregulation patterns in AD; the temporal ordering of non-neuronal changes relative to tau spread was identified as a key open question.
Primary hypothesis: APO
Skeptic critique for analysis db9a224d-3ebb-429c-8f02-b703d71ca211: Non-Neuronal Transcriptional Changes Preceding Tau Propagation as Early AD Biomarkers
The source paper motivates the gap, but motivation is not causal evidence. The main threat is that the observed association in Single-cell spatial transcriptomics reveals distinct patterns of dysregulation in non-neuronal cell types in Alzheimer's disease could be downstream of disease stage, tissue composition, survival bias, or batch structure. The specific concern here is: lipid droplet accumulation may be compensatory rather than causal,
Domain expert assessment for analysis db9a224d-3ebb-429c-8f02-b703d71ca211: Non-Neuronal Transcriptional Changes Preceding Tau Propagation as Early AD Biomarkers
The practical path is feasible but should be staged. Stage 1 should reanalyze or collect human data at the needed resolution, preserving pathology, sex/genotype, region, and disease-stage covariates when relevant. Stage 2 should test APOE ε4-driven microglial lipid handling in a model where the proximal readout can be measured before overt toxicity. Stage 3 should connect the readout to a translational biomarker or intervention point
{
"ranked_hypotheses": [
{
"title": "APOE \u03b54-driven microglial lipid handling as proximal driver in Non-Neuronal Transcriptional Changes Preceding Tau Propagation as Early AD Biomarkers",
"description": "APOE \u03b54-driven microglial lipid handling should produce a measurable proximal phenotype before late disease pathology. The decisive test is isogenic APOE3/APOE4 microglia co-cultured with amyloid-bearing neurons, lipidomics, and phagocytosis/degradation assays.",
"target_gene": "RNA-",
"dimension_scores": {
"evidence_strength": 0.62,
"nov
No price history recorded yet
No clinical trials data available
No linked papers yet
Freshness score = exp(-age×ln2/5): halves every 5 years. Green >0.6, Amber 0.3–0.6, Red <0.3.
No citation freshness data yet. Export bibliography — run scripts/audit_citation_freshness.py to populate.
Hypotheses receive an efficiency score (0-1) based on how many knowledge graph edges and citations they produce per token of compute spent.
High-efficiency hypotheses (score >= 0.8) get a price premium in the market, pulling their price toward $0.580.
Low-efficiency hypotheses (score < 0.6) receive a discount, pulling their price toward $0.420.
Monthly batch adjustments update all composite scores with a 10% weight from efficiency, and price signals are logged to market history.
Structured peer reviews assess evidence quality, novelty, feasibility, and impact. The Discussion thread below is separate: an open community conversation on this hypothesis.
No DepMap CRISPR Chronos data found for APOE.
Run python3 scripts/backfill_hypothesis_depmap.py to populate.
No curated ClinVar variants loaded for this hypothesis.
Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.
No governance decisions recorded for this hypothesis.
Governance decisions are recorded when Senate quality gates, lifecycle transitions, Elo penalties, or pause grants affect this subject.
No knowledge graph edges recorded
neurodegeneration | 2026-04-27 | open
No comments yet. Be the first to comment!